Literature DB >> 25431478

Eculizumab fails to inhibit generation of C5a in vivo.

Richard M Burwick1, Nicholas R Burwick2, Bruce B Feinberg3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25431478     DOI： 10.1182/blood-2014-07-589366

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

Authors:  Elena B Volokhina; Grethe Bergseth; Nicole C A J van de Kar; Lambertus P van den Heuvel; Tom Eirik Mollnes
Journal:  Blood       Date:  2015-07-09       Impact factor: 22.113

2.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 3.  The Complement System and Preeclampsia.

Authors:  Jean F Regal; Richard M Burwick; Sherry D Fleming
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 4.  The complement system and adverse pregnancy outcomes.

Authors:  Jean F Regal; Jeffrey S Gilbert; Richard M Burwick
Journal:  Mol Immunol       Date:  2015-03-21       Impact factor: 4.407

5.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

6.  Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.

Authors:  Philippe Gatault; Guillaume Brachet; David Ternant; Danielle Degenne; Guillaume Récipon; Christelle Barbet; Emmanuel Gyan; Valérie Gouilleux-Gruart; Cécile Bordes; Alexandra Farrell; Jean Michel Halimi; Hervé Watier
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

7.  The Value of Targeting Complement Components in Asthma.

Authors:  Marwa M E Mohamed; Alicia D Nicklin; Cordula M Stover
Journal:  Medicina (Kaunas)       Date:  2020-08-12       Impact factor: 2.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.